JP2018535997A - ｃｔＤＮＡにＰＩＫ３ＣＡ変異を有するために事前選択された患者におけるＰＩ３Ｋ阻害剤を用いた癌の処置 - Google Patents

ｃｔＤＮＡにＰＩＫ３ＣＡ変異を有するために事前選択された患者におけるＰＩ３Ｋ阻害剤を用いた癌の処置 Download PDF

Info

Publication number
JP2018535997A
JP2018535997A JP2018528592A JP2018528592A JP2018535997A JP 2018535997 A JP2018535997 A JP 2018535997A JP 2018528592 A JP2018528592 A JP 2018528592A JP 2018528592 A JP2018528592 A JP 2018528592A JP 2018535997 A JP2018535997 A JP 2018535997A
Authority
JP
Japan
Prior art keywords
cancer
patient
pyridin
amide
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018528592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535997A5 (enExample
Inventor
トマソ，エマニュエル ディ
トマソ，エマニュエル ディ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2018535997A publication Critical patent/JP2018535997A/ja
Publication of JP2018535997A5 publication Critical patent/JP2018535997A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018528592A 2015-12-03 2016-11-30 ｃｔＤＮＡにＰＩＫ３ＣＡ変異を有するために事前選択された患者におけるＰＩ３Ｋ阻害剤を用いた癌の処置 Pending JP2018535997A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262620P 2015-12-03 2015-12-03
US62/262,620 2015-12-03
PCT/IB2016/057208 WO2017093905A1 (en) 2015-12-03 2016-11-30 Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna

Publications (2)

Publication Number Publication Date
JP2018535997A true JP2018535997A (ja) 2018-12-06
JP2018535997A5 JP2018535997A5 (enExample) 2020-03-05

Family

ID=57517943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018528592A Pending JP2018535997A (ja) 2015-12-03 2016-11-30 ｃｔＤＮＡにＰＩＫ３ＣＡ変異を有するために事前選択された患者におけるＰＩ３Ｋ阻害剤を用いた癌の処置

Country Status (13)

Country Link
US (2) US20180353515A1 (enExample)
EP (1) EP3383391A1 (enExample)
JP (1) JP2018535997A (enExample)
KR (1) KR20180084830A (enExample)
CN (1) CN108366998A (enExample)
AU (1) AU2016362683B2 (enExample)
CA (1) CA3006419A1 (enExample)
HK (1) HK1253737A1 (enExample)
IL (1) IL259716A (enExample)
MX (1) MX2018006777A (enExample)
RU (1) RU2018123524A (enExample)
TW (1) TW201722429A (enExample)
WO (1) WO2017093905A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355545A1 (en) * 2018-10-15 2021-11-18 The Johns Hopkins University Methods and materials for assessing and treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 投与および治療方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010145A2 (en) 2003-07-05 2005-02-03 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
ES2537633T3 (es) 2004-03-02 2015-06-10 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI471134B (zh) 2007-09-12 2015-02-01 Genentech Inc 肌醇磷脂３－激酶抑制劑化合物及化療劑之組合及使用方法
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
MX2014011682A (es) * 2012-03-29 2015-01-22 Novartis Ag Diagnostico farmaceutico.
EP3842554B1 (en) * 2014-05-09 2022-12-14 Memorial Sloan Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 投与および治療方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRISTIAN MASSACESI; ET AL: "OVERCOMING PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) ACTIVATION IN BREAST CANCER: EMERGING 以下備考", THE JOURNAL OF ONCOPATHOLOGY, vol. 3, no. 1, JPN5019000778, 1 February 2015 (2015-02-01), pages 27 - 39, ISSN: 0004577159 *
OSHIRO C; ET AL: "PIK3CA MUTATIONS IN SERUM DNA ARE PREDICTIVE OF RECURRENCE IN PRIMARY BREAST CANCER PATIENTS", BREAST CANCER RESEARCH AND TREATMENT, vol. VOL. 150, NR. 2, JPN5019000782, 4 March 2015 (2015-03-04), US, pages 299 - 307, ISSN: 0004577160 *

Also Published As

Publication number Publication date
CA3006419A1 (en) 2017-06-08
CN108366998A (zh) 2018-08-03
US20200138824A1 (en) 2020-05-07
AU2016362683A1 (en) 2018-05-31
RU2018123524A3 (enExample) 2020-04-02
KR20180084830A (ko) 2018-07-25
US20180353515A1 (en) 2018-12-13
IL259716A (en) 2018-07-31
TW201722429A (zh) 2017-07-01
MX2018006777A (es) 2018-08-01
AU2016362683B2 (en) 2019-11-07
WO2017093905A1 (en) 2017-06-08
EP3383391A1 (en) 2018-10-10
RU2018123524A (ru) 2020-01-09
HK1253737A1 (zh) 2019-06-28

Similar Documents

Publication Publication Date Title
Gonzalez-Angulo et al. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
Martín et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2–advanced breast cancer (BELLE-4)
Fedorenko et al. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
KR102125496B1 (ko) 파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법
Schwarz et al. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer
Kennedy et al. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making
Mazza et al. Treating EGFR mutation resistance in non-small cell lung cancer–role of osimertinib
KR20170005419A (ko) Pi3k 억제제 피크틸리시브로 pr-양성 내강 a형 유방암을 치료하는 방법
RS55053B1 (sr) Prediktori za lečenje kancera
JP2024519060A (ja) ソトラシブ投与レジメン
JP2023500950A (ja) マントル細胞リンパ腫（ｍｃｌ）対象を特定するための鉄スコアおよびインビトロ方法ならびに治療的使用および方法
WO2012103060A1 (en) Method of administration and treatment
WO2009021674A1 (en) Predictive markers for egfr inhibitor treatment
JP2018535997A (ja) ｃｔＤＮＡにＰＩＫ３ＣＡ変異を有するために事前選択された患者におけるＰＩ３Ｋ阻害剤を用いた癌の処置
KR20140135198A (ko) Pak1 억제제로 흑색종을 치료하는 방법
Goemans et al. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657
WO2009021683A2 (en) Predictive marker for egfr inhibitor treatment
CN101827947B (zh) Egfr抑制剂治疗的预测性标记物
US20230377684A1 (en) Novel prediction method and gene signatures for the treatment of cancer
Howell Lung Cancer Cells Survive EGFR TKI Exposure Through Upregulation of Cholesterol Synthesis
Crombie et al. Advances in drug‐based therapies in chronic lymphocytic leukemia and future prospects
WO2025245123A1 (en) Methods and materials for assessing cancer treatments
KR20250065332A (ko) 변형된 stk11 활성 또는 발현을 갖는 암을 치료하기 위한 hdac 억제제
Dewaele et al. Co-activated PDGFRA and EGFR are potential therapeutic targets in intimal sarcoma
EP2188392A1 (en) Predictive marker for egfr inhibitor treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210824